Is Mobic affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2C9

Mobic is affected by pharmacogenetics through the CYP2C9 gene. Your genotype for this gene can change how your body processes Mobic, which can affect both how well it works and how well you tolerate it. The strongest evidence level on this page is Strong, based on CPIC or FDA guidelines.

What's in Mobic

meloxicam affected by CYP2C9

Affected by CYP2C9 · CPIC, FDA · Strong evidence

Read the full meloxicam genetics guide →

Meloxicam phenotype recommendations

Published guidance from CPIC and FDA on how meloxicam should be dosed or substituted based on your CYP2C9 phenotype.

Phenotype	What it means	Recommendation	Evidence
Normal Metabolizer CYP2C9	Your body processes this drug normally, so the usual starting dose applies.	CPIC Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. FDA Initiate therapy with recommended starting dose.	Strong
Intermediate Metabolizer CYP2C9	Your body slows the drug slightly, but usually the normal starting dose is fine.	CPIC Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. CPIC Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady-state is reached (at least 7 days). Carefully monitor adverse events, such as blood pressure and kidney function, during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo, or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. FDA Initiate therapy with recommended starting dose. Monitor for adverse reactions.	Moderate
Poor Metabolizer CYP2C9	Your body processes the drug very slowly, so it’s safer to use a different medicine or one less affected by your genetics.	CPIC + CPIC Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo, or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. FDA Consider reducing the dose due to higher systemic concentrations. Monitor closely for adverse reactions.	Moderate
Indeterminate CYP2C9	The impact of your genotype on response to this drug is unknown.	CPIC + FDA Initiate therapy with recommended starting dose.	—
Not available CYP2C9	The impact of your genotype on response to this drug is unknown.	CPIC + FDA Initiate therapy with recommended starting dose.	—

Sources: CPIC, FDA

The gene behind the guidance

CYP2C9 Cytochrome P450 2C9

CYP2C9 metabolizes warfarin, phenytoin, celecoxib, and some NSAIDs. Variants that reduce its activity are most consequential for warfarin, where even small changes in drug clearance translate into very different doses (and a real bleeding risk if missed).

Poor metabolizers need substantially lower warfarin doses to hit the same INR target.

See all drugs affected by CYP2C9 →

Browse the full drug-class: Pain medications.

Related medications

Find out how your genetics affect Mobic

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.